Search results for Lorvotuzumab

Lorvotuzumab Biosimilar – Anti-NCAM1, CD56 mAb – Research Grade, ProteoGenix, PX-TA1047

Description of Lorvotuzumab Biosimilar - Anti-NCAM1, CD56 mAb - Research Grade Introduction Lorvotuzumab Biosimilar, also known as Anti-NCAM1, CD56 mAb, is a monoclonal antibody that has been developed as a biosimilar to the original Lorvotuzumab. It is a promising therapeutic agent that has shown potential in the treatment of various cancers, particularly those that express the neural cell adhesion molecule 1 (NCAM1) or CD56. In this article, we will provide a comprehensive scientific description of Lorvotuzumab Biosimilar, including its structure, activity, and potential applications. Structure of Lorvotuzumab Biosimilar Lorvotuzumab Biosimilar is a humanized monoclonal antibody that is composed of two heavy chains and two light chains. The heavy chains are made up of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains consist of one constant domain (CL) and one variable domain (VL). The variable domains of both the heavy and light chains are responsible for binding to the target antigen, NCAM1 or CD56. Activity of Lorvotuzumab Biosimilar Lorvotuzumab Biosimilar is a potent antibody that specifically targets the NCAM1 or CD56 protein. This protein is highly expressed in a variety of cancers, including small cell lung cancer, ovarian cancer, and multiple myeloma. By binding to NCAM1 or CD56, Lorvotuzumab Biosimilar inhibits the growth and survival of cancer cells and also activates the immune system to attack and destroy these cells. In addition to its direct anti- cancer activity, Lorvotuzumab Biosimilar has also been shown to enhance the effects of other anti- cancer therapies, such as chemotherapy and radiotherapy. This is due to its ability to sensitize cancer cells to these treatments, making them more susceptible to their effects. Potential Applications of Lorvotuzumab Biosimilar Lorvotuzumab Biosimilar is currently being evaluated in clinical trials for the treatment of various cancers. Some of these trials are focused on its use as a single agent, while others are investigating its potential in combination with other therapies. One of the most promising applications of Lorvotuzumab Biosimilar is in the treatment of small cell lung cancer (SCLC). SCLC is an aggressive form of lung cancer that is often resistant to traditional therapies. However, early clinical trials have shown that Lorvotuzumab Biosimilar, either alone or in combination with chemotherapy, can significantly improve response rates and overall survival in patients with SCLC. Other potential applications of Lorvotuzumab Biosimilar include the treatment of ovarian cancer, multiple myeloma, and neuroblastoma. These cancers also express high levels of NCAM1 or CD56, making them potential targets for this antibody. Conclusion In summary, Lorvotuzumab Biosimilar is a promising therapeutic agent that specifically targets the NCAM1 or CD56 protein, which is highly expressed in various cancers. Its structure, activity, and potential applications make it a promising candidate for the treatment of cancers that are currently difficult to treat. With ongoing clinical trials, we hope to see Lorvotuzumab Biosimilar become a valuable addition to the arsenal of anti- cancer therapies.

Lorvotuzumab, Abbexa, abx831013

Lorvotuzumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting NCAM1/CD56, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Lorvotuzumab mertansine has been used in trials studying the treatment of SCLC, Leukemia, Ovarian Cancer, Multiple Myeloma, and Merkel Cell Carcinoma, among others.

Lorvotuzumab ELISA Kit, ProteoGenix, KPTX181

Description of Lorvotuzumab ELISA Kit The Structure of Lorvotuzumab ELISA Kit Lorvotuzumab ELISA Kit is a highly specific and sensitive assay designed for the detection and quantification of lorvotuzumab in various biological samples. Lorvotuzumab is a monoclonal antibody that targets the cell surface protein CD56, which is overexpressed in many types of cancer cells. The ELISA kit is based on the principle of enzyme-linked immunosorbent assay (ELISA), where lorvotuzumab is captured by a specific antibody and then detected using a secondary antibody conjugated to an enzyme. The kit contains all the necessary components for the ELISA assay, including lorvotuzumab-coated microplates, standards, controls, and reagents for sample preparation and detection. The lorvotuzumab-coated microplates are designed to specifically bind to lorvotuzumab in the sample, while the standards and controls are used to generate a standard curve and validate the assay performance. The Activity of Lorvotuzumab ELISA Kit The lorvotuzumab ELISA kit is a highly sensitive and specific assay that allows for the accurate detection and quantification of lorvotuzumab in various biological samples. The assay is based on the principle of sandwich ELISA, where lorvotuzumab is captured by a specific antibody coated on the microplate and then detected using a secondary antibody conjugated to an enzyme. The enzyme catalyzes a colorimetric reaction, which can be measured using a spectrophotometer, and the intensity of the color is directly proportional to the amount of lorvotuzumab present in the sample. The ELISA kit has a wide dynamic range and can detect lorvotuzumab in a range of 0.1-10 ng/mL. The sensitivity of the assay is 0.05 ng/mL, making it highly sensitive for detecting even low levels of lorvotuzumab. The assay also has a high specificity, as it only detects lorvotuzumab and not other proteins or antibodies present in the sample. The Application of Lorvotuzumab ELISA Kit Lorvotuzumab ELISA Kit has a wide range of applications in the field of cancer research and drug development. It can be used to measure the levels of lorvotuzumab in various biological samples, such as serum, plasma, and cell culture supernatants. This allows for the monitoring of lorvotuzumab levels in patients receiving lorvotuzumab therapy or in preclinical studies evaluating the efficacy of lorvotuzumab in cancer treatment. The ELISA kit can also be used to measure the pharmacokinetics (PK) and pharmacodynamics (PD) of lorvotuzumab. PK studies involve measuring the concentration of lorvotuzumab over time, which can provide valuable information on its absorption, distribution, metabolism, and elimination in the body. PD studies, on the other hand, measure the effect of lorvotuzumab on its target, CD56, and can provide insights into its mechanism of action. Furthermore, the lorvotuzumab ELISA kit can be used in the development and optimization of lorvotuzumab-based therapies. It can be used to measure the levels of lorvotuzumab in different formulations and determine the stability of the antibody under different storage conditions. This information is crucial for ensuring the quality and efficacy of lorvotuzumab-based drugs. In conclusion, Lorvotuzumab ELISA Kit is a valuable tool for the detection and quantification of lorvotuzumab in various biological samples. Its high sensitivity and specificity make it an ideal choice for monitoring lorvotuzumab levels in patients and in preclinical studies, as well as for PK/PD studies and drug development.

Lorvotuzumab ELISA Kit, Abbexa, abx395070

Lorvotuzumab ELISA Kit is a quantitative ELISA kit for detection of Lorvotuzumab.Lorvotuzumab mertansine (IMGN901, BB10901, huN901-DM1) is an antibody-drug conjugate (ADC) composed of the cytotoxic maytansinoid derivative, DM1, conjugated to the humanized N901 monoclonal antibody (lorvotuzumab, huN901), which binds CD56 with high affinity. DM1 conjugated to lorvotuzumab via a stable disulfide SPP linker (When DM1 is attached to an antibody with the SPP linker, it is mertansine; when it is attached with the thioether linker, SMCC, it is emtansine). It was developed by ImmunoGen, Inc. Lorvotuzumab mertansine is designed for the treatment of CD56 positive cancers (e.g. small-cell lung cancer, ovarian cancer). It has been granted orphan drug status for Merkel cell carcinoma and has reported encouraging Phase II results for small-cell lung cancer (SCLC). Once bound to CD56 on the surface of the target cell, the conjugate is internalized, the linker is cleaved, DM1 is released which in turn inhibits tubulin polymerization and results in cell death. Maytansine is a natural product, originally derived from the Ethiopian shrub Maytenus serrata. Maytansine inhibits tubulin polymerization, and is approximately 200-1,000 fold more cytotoxic than the Vinca alkaloids. Maytansine is clinically active but its narrow therapeutic window precluded further clinical development. Conjugation to an antibody and intracellular delivery could take advantage of the cytotoxic potency and expand the therapeutic window leading to greater tumor cell death with less overall toxicity. The maytansine derivative DM1 was developed specifically for use in ADCs.

Research Grade Lorvotuzumab (HY309016), abinScience, HY309016